Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib

By                      

Experimental and Therapeutic Medicine, Vol. 2, Iss. 4, 2011-01 ,pp. : 685-693

Spandidos Publications

Access to resources Recommend Favorite

Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer

By          

Oncology Reports, Vol. 28, Iss. 2, 2012-01 ,pp. : 721-727

Spandidos Publications

Access to resources Recommend Favorite

Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group Experience

By Hotta Katsuyuki   Ueoka Hiroshi   Kiura Katsuyuki   Tabata Masahiro   Ogino Atsuko   Umemura Shigeki   Harita Shingo   Gemba Kenichi   Yonei Toshiro   Bessho Akihiro   Maeda Tadashi   Tanimoto Mitsune  

Acta Oncologica, Vol. 44, Iss. 7, 2005-10 ,pp. : 717-722

Informa Healthcare

Access to resources Recommend Favorite

Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG0803)

By Wu Y.-L.   Zhou C.   Cheng Y.   Lu S.   Chen G.-Y.   Huang C.   Huang Y.-S.   Yan H.-H.   Ren S.   Liu Y.   Yang J.-J.  

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 993-999

Oxford University Press

Access to resources Recommend Favorite

Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics

By Motoshima Kohei   Nakamura Yoichi   Sano Kazumi   Ikegami Yoji   Ikeda Takaya   Mizoguchi Kosuke   Takemoto Shinnosuke   Fukuda Minoru   Nagashima Seiji   Iida Tetsuya   Tsukamoto Kazuhiro   Kohno Shigeru  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 6, 2013-12 ,pp. : 1299-1304

Springer Publishing Company

Access to resources Recommend Favorite